Claudia Moneta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Claudia Moneta has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Laura Fugazzola
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
3 shared publications - Simone De Leo
Department of Endocrinology, ASST Santi Paolo e Carlo, Milan, Italy
3 shared publications - Carla Colombo
Department of Endocrine and Metabolic Diseases, Endocrine Oncology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy
2 shared publications - Marina Lugaresi
Department of Health Sciences, University of Milan , 20142 Milan, Italy
2 shared publications - Matteo Trevisan
Department of Health Sciences, University of Milan
2 shared publications Alessia De Luca
Department of Medical Biotechnologies and Translational Medicine, University of Milan
1 shared publication
Latest Publications
- Open Access
- 6 July 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (8) , bvag154
Development of a sensitive plasma lenvatinib quantification method and validation in thyroid cancer patients
Context: Lenvatinib (LEN) is effective in the treatment of radioactive iodine refractory differentiated thyroid cancer (DTC), though it is associated with frequent and potentially severe adverse events (AEs). The dose dependency of LEN-related toxicity remains unclear, since no data are available on this topic. Objective: This study aimed to investigate the relationship between LEN dose and plasma concentrations in real-life patients by a novel and validated method for quantifying LEN in plasma samples. Design and setting: A sensitive high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC–MS/MS) assay for LEN quantification in plasma was set up, with a wide analytical range (0.7-500 ng/mL). Consecutive plasma samples from 19 patients with radioactive iodine-refractory, metastatic DTC were analyzed. Results: A positive correlation between the administered LEN dose and plasma concentrations was found, particularly in patients on low doses (<18 mg daily). Linear mixed-effects models (LMMs) demonstrated significant interindividual variability in plasma LEN concentrations, contributing to 17% to 28% of the total variance. This variability was more pronounced at higher doses (≥18 mg), being more likely the consequence of LEN-related AEs than of a dose-dependent effect. Conclusion: This is the first real-life evaluation of interindividual LEN pharmacokinetics variability in advanced DTC patients, obtained by means of the newly developed HPLC–MS/MS method. Our results suggest that the dose–response relationship of LEN in radioactive iodine-refractory DTC may be more complex than previously understood, with substantial interpatient variability and dose-dependent effects. Further studies are needed to determine the implications of our findings in the clinical management of these patients.
- 6 July 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (8) , bvag154
Open AccessDevelopment of a sensitive plasma lenvatinib quantification method and validation in thyroid cancer patients
Context: Lenvatinib (LEN) is effective in the treatment of radioactive iodine refractory differentiated thyroid cancer (DTC), though it is associated with frequent and potentially severe adverse events (AEs). The dose dependency of LEN-related toxicity remains unclear, since no data are available on this topic. Objective: This study aimed to investigate the relationship between LEN dose and plasma concentrations in real-life patients by a novel and validated method for quantifying LEN in plasma samples. Design and setting: A sensitive high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC–MS/MS) assay for LEN quantification in plasma was set up, with a wide analytical range (0.7-500 ng/mL). Consecutive plasma samples from 19 patients with radioactive iodine-refractory, metastatic DTC were analyzed. Results: A positive correlation between the administered LEN dose and plasma concentrations was found, particularly in patients on low doses (<18 mg daily). Linear mixed-effects models (LMMs) demonstrated significant interindividual variability in plasma LEN concentrations, contributing to 17% to 28% of the total variance. This variability was more pronounced at higher doses (≥18 mg), being more likely the consequence of LEN-related AEs than of a dose-dependent effect. Conclusion: This is the first real-life evaluation of interindividual LEN pharmacokinetics variability in advanced DTC patients, obtained by means of the newly developed HPLC–MS/MS method. Our results suggest that the dose–response relationship of LEN in radioactive iodine-refractory DTC may be more complex than previously understood, with substantial interpatient variability and dose-dependent effects. Further studies are needed to determine the implications of our findings in the clinical management of these patients.
- Open Access
- 17 April 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (10) , 2883-2889
VALIDATION OF THE 2025 ATA RISK STRATIFICATION SYSTEM IN A COHORT OF PATIENTS WITH PAPILLARY THYROID CARCINOMA
Context: The updated risk stratification system for papillary thyroid cancer (PTC) introduced by the 2025 American Thyroid Association (ATA) guidelines has not yet been validated in a real-world setting. Design: Retrospective observational study Setting: Tertiary care center Patients: Data from 670 PTC patients with complete histopathological and final disease outcome were included. Main Outcome measures: We evaluated how patients previously classified by the 2015 ATA risk stratification system are redistributed according to the updated version and assessed the impact of reclassification on final disease outcome prediction. Results: The reclassification according to the 2025 ATA risk stratification showed that the proportion of “low-risk” PTC decreased by 22.2%, while “intermediate-risk” and “high-risk” PTC increased by 41.7 and 14.9%, respectively. Cross-comparison between the two stratification systems revealed that structural disease persistence in the 2025 “low-risk” and “high-risk” classes was comparable. The 2025 “intermediate-high-risk” class was similar to the former “intermediate-risk” class, whereas the “low-intermediate-risk” class emerged as a new class, with a risk of structural disease persistence higher than that of the 2015 “low-risk” class (p = 0.003), but lower than that of the 2015 “intermediate-risk” class (p = 0.012). Conclusions: In a real-life context, the 2025 ATA risk stratification system led to a shift toward higher-risk classes. The newly defined “low-intermediate-risk” class was the only class that significantly diverged from the classes of the 2015 stratification, with a risk of structural recurrence between the prior “low-risk” and “intermediate-risk” classes, highlighting the need for dedicated prospective studies to address proper management of this newly-defined group of patients.
- 17 April 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (10) , 2883-2889
Open AccessVALIDATION OF THE 2025 ATA RISK STRATIFICATION SYSTEM IN A COHORT OF PATIENTS WITH PAPILLARY THYROID CARCINOMA
Context: The updated risk stratification system for papillary thyroid cancer (PTC) introduced by the 2025 American Thyroid Association (ATA) guidelines has not yet been validated in a real-world setting. Design: Retrospective observational study Setting: Tertiary care center Patients: Data from 670 PTC patients with complete histopathological and final disease outcome were included. Main Outcome measures: We evaluated how patients previously classified by the 2015 ATA risk stratification system are redistributed according to the updated version and assessed the impact of reclassification on final disease outcome prediction. Results: The reclassification according to the 2025 ATA risk stratification showed that the proportion of “low-risk” PTC decreased by 22.2%, while “intermediate-risk” and “high-risk” PTC increased by 41.7 and 14.9%, respectively. Cross-comparison between the two stratification systems revealed that structural disease persistence in the 2025 “low-risk” and “high-risk” classes was comparable. The 2025 “intermediate-high-risk” class was similar to the former “intermediate-risk” class, whereas the “low-intermediate-risk” class emerged as a new class, with a risk of structural disease persistence higher than that of the 2015 “low-risk” class (p = 0.003), but lower than that of the 2015 “intermediate-risk” class (p = 0.012). Conclusions: In a real-life context, the 2025 ATA risk stratification system led to a shift toward higher-risk classes. The newly defined “low-intermediate-risk” class was the only class that significantly diverged from the classes of the 2015 stratification, with a risk of structural recurrence between the prior “low-risk” and “intermediate-risk” classes, highlighting the need for dedicated prospective studies to address proper management of this newly-defined group of patients.
- 1 January 2023
- Published by SAGE Publications in Thyroid®
- Vol. 33 (1) , 74-81
Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting
Background: Treatment of advanced thyroid cancer (TC) with antiangiogenic drugs, including lenvatinib (LEN), associates with several adverse events. Hypocalcemia has been reported in registration studies, but scanty data are available from real-life cohorts. Aim of our study was to report the prevalence and to describe the characteristics and the management of hypocalcemia in patients on LEN treatment. Methods: We enrolled consecutive patients, followed-up at our single tertiary center, who received LEN for at least six months for advanced TC. Phosphocalcic metabolism and bone mineral density were evaluated during treatment. Results: We included 25 patients treated for a mean of 29 ± 19 months (range 6-68 months). Hypocalcemia occurred in 6/25 patients (24%), being of grade ≥3 in 2/25 patients (8%), and recurrent in 4/6 patients. Median time to onset of hypocalcemia was 3 months (range 0.5-13 months) from LEN start. No differences were found between who developed and who did not develop hypocalcemia regarding either starting and mean dose of LEN or several clinico-pathological characteristics. Patients who developed hypocalcemia had more frequently, albeit not significantly, osteoporosis (75% vs 33.3%) and gastrointestinal side effects (diarrhea, vomit/nausea, weight loss). During the hypocalcemic crisis, the 2 patients with grade ≥3 hypocalcemia had low magnesium and low or inappropriately normal parathormone (PTH) levels, while 2/3 patients with grade 2 hypocalcemia had a secondary hyperparathyroidism. Hypocalcemia was managed with calcium oral supplementation or intravenous treatment and with transient LEN withdrawal, when necessary. Conclusions: Hypocalcemia is frequent during LEN treatment, with a prevalence higher than that reported in the registration SELECT trial (24 vs 6.9%). Both PTH-dependent and PTH-independent mechanisms have been shown to lead to hypocalcemia in the present cohort. Moreover, osteoporosis and gastrointestinal side effects could be considered as predisposing conditions, though further studies are needed to get more insights into other possible risk factors to monitor. Since hypocalcemia can be a life-threatening condition, monitoring of calcium levels is required, in particular during the first year of treatment. Oral calcium supplementation can correct hypocalcemia if promptly diagnosed; however, up to 10% of patients may require intravenous treatment and LEN transient discontinuation.
- 1 January 2023
- Published by SAGE Publications in Thyroid®
- Vol. 33 (1) , 74-81
Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting
Background: Treatment of advanced thyroid cancer (TC) with antiangiogenic drugs, including lenvatinib (LEN), associates with several adverse events. Hypocalcemia has been reported in registration studies, but scanty data are available from real-life cohorts. Aim of our study was to report the prevalence and to describe the characteristics and the management of hypocalcemia in patients on LEN treatment. Methods: We enrolled consecutive patients, followed-up at our single tertiary center, who received LEN for at least six months for advanced TC. Phosphocalcic metabolism and bone mineral density were evaluated during treatment. Results: We included 25 patients treated for a mean of 29 ± 19 months (range 6-68 months). Hypocalcemia occurred in 6/25 patients (24%), being of grade ≥3 in 2/25 patients (8%), and recurrent in 4/6 patients. Median time to onset of hypocalcemia was 3 months (range 0.5-13 months) from LEN start. No differences were found between who developed and who did not develop hypocalcemia regarding either starting and mean dose of LEN or several clinico-pathological characteristics. Patients who developed hypocalcemia had more frequently, albeit not significantly, osteoporosis (75% vs 33.3%) and gastrointestinal side effects (diarrhea, vomit/nausea, weight loss). During the hypocalcemic crisis, the 2 patients with grade ≥3 hypocalcemia had low magnesium and low or inappropriately normal parathormone (PTH) levels, while 2/3 patients with grade 2 hypocalcemia had a secondary hyperparathyroidism. Hypocalcemia was managed with calcium oral supplementation or intravenous treatment and with transient LEN withdrawal, when necessary. Conclusions: Hypocalcemia is frequent during LEN treatment, with a prevalence higher than that reported in the registration SELECT trial (24 vs 6.9%). Both PTH-dependent and PTH-independent mechanisms have been shown to lead to hypocalcemia in the present cohort. Moreover, osteoporosis and gastrointestinal side effects could be considered as predisposing conditions, though further studies are needed to get more insights into other possible risk factors to monitor. Since hypocalcemia can be a life-threatening condition, monitoring of calcium levels is required, in particular during the first year of treatment. Oral calcium supplementation can correct hypocalcemia if promptly diagnosed; however, up to 10% of patients may require intravenous treatment and LEN transient discontinuation.